NPWR Investors Have Opportunity to Lead NET Power Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, May 5, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NET Power Inc. ('Net Power' or 'the Company') (NYSE: NPWR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between June 9, 2023 and March 7, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before June 17, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Net Power was unlikely to complete Project Permian on time and on budget due to supply chain issues and multiple issues specific to the site and region. The Company's projections about the time and financial resources required to complete Project Permian were not based in reality. The Company's financial results and business would be negatively impacted by the delays and cost overruns associated with Project Permian. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Net Power, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law FirmBrian Schall, Esq.,www.schallfirm.comOffice: 310-301-3335info@schallfirm.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
11 hours ago
- Malaysian Reserve
On World Oceans Day 2025, POWERCHINA Highlights Commitment to Ocean Sustainability
BEIJING, June 8, 2025 /PRNewswire/ — Power Construction Corporation of China ('POWERCHINA' or 'the Company')reaffirms its long-term commitment to protecting marine ecosystems and promoting sustainable water resource development in recognition of World Oceans Day on June 8, themed, 'Wonder: Sustaining What Sustains Us.' A global leader in desalination and ecological construction, the Company integrates ocean stewardship into its projects and responsible corporate practices to support a healthier, more resilient planet. The ocean is a vital support for life on Earth. However, it is now facing increasingly severe threats. Meanwhile, the access to clean water is also becoming a common challenge faced by the world, and the importance of seawater desalination technology to human health and economic growth is becoming more and more prominent. POWERCHINA has developed some of the world's largest and most advanced desalination projects, including the 900,000-ton Taweelah Desalination Plant in Abu Dhabi, which is the largest reverse osmosis seawater desalination facility globally to date. The plant supplies drinking water to nearly 2 million people, using cutting-edge technology to boost efficiency while minimising ecological disruption. As the world's largest seawater desalination engineering, procurement, and construction (EPC) contractor, POWERCHINA has built a strong technological foundation and a comprehensive system in desalination. The Company has completed several major projects across the UAE, Saudi Arabia, and Dubai, converting seawater into clean drinking water and helping to meet surging demand in arid regions. POWERCHINA has provided clean water to millions in the Middle East and North Africa, easing regional water shortages and supporting sustainable development. POWERCHINA integrates marine conservation into all project phases, from early-stage environmental impact assessments to biodiversity protection measures. Along coastal areas, the Company schedules construction to avoid sensitive periods like sea turtle nesting seasons and carries out marine plant relocation when needed. These actions are complemented by public education initiatives and stakeholder engagement campaigns that foster awareness and local support for marine sustainability. At a marine ecosystem public welfare activity organized by POWERCHINA, Major Ali, the president of EMEG said: 'Watching marine conservation films and listening to expert lectures have made me realize the crucial role that mangroves play in protecting the marine ecological environment, promoting carbon sequestration, and mitigating climate change. I have also come to understand the importance of protecting marine species such as sea turtles, as well as the specific methods for protecting marine ecosystems. Every action we take can make a difference, and participating in this activity is a way for me to express my commitment to protecting the ocean.' POWERCHINA sees marine protection as central to its global sustainable development strategy, answering calls to restore ocean health and biodiversity. The Company invests in green infrastructure and marine resilience to help balance human activity with vital ecosystems. As a global leader in clean, low-carbon energy construction, POWERCHINA is committed to sustainable, green development. It actively assumes environmental responsibilities and contributes to building a healthier, more beautiful environment in the communities where it operates. Photo – View original content:
Malaysian Reserve
19 hours ago
- Malaysian Reserve
DV INVESTOR DEADLINE: DoubleVerify Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 7, 2025 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of DoubleVerify Holdings, Inc. (NYSE: DV) common stock between November 10, 2023 and February 27, 2025, inclusive (the 'Class Period'), have until July 21, 2025 to seek appointment as lead plaintiff of the DoubleVerify class action lawsuit. Captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. DoubleVerify Holdings, Inc., No. 25-cv-04332 (S.D.N.Y.), the DoubleVerify class action lawsuit charges DoubleVerify as well as certain of DoubleVerify's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the DoubleVerify class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: DoubleVerify provides media effectiveness platforms. The DoubleVerify class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) DoubleVerify's customers were shifting their ad spending from open exchanges to closed platforms, where DoubleVerify's technological capabilities were limited and competed directly with native tools provided by platforms like Meta Platforms and Amazon; (ii) DoubleVerify's ability to monetize on its Activation Services was limited because the development of its technology for closed platforms was significantly more expensive and time-consuming than disclosed to investors; (iii) DoubleVerify's Activation Services in connection with certain closed platforms would take several years to monetize; (iv) DoubleVerify's competitors were better positioned to incorporate AI into their offerings on closed platforms, which impaired DoubleVerify's ability to compete effectively and adversely impacted DoubleVerify's profits; (v) DoubleVerify systematically overbilled its customers for ad impressions served to declared bots operating out of known data center server farms; and (vi) DoubleVerify's risk disclosures were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities. The DoubleVerify class action lawsuit further alleges that on February 28, 2024, DoubleVerify issued lower revenue growth expectations for the first quarter of 2024 due to 'a slow start by brand advertisers and a slow ramp by recently signed' customers. On this news, the price of DoubleVerify stock fell more than 21%, according to the complaint. Then, on May 7, 2024, as the DoubleVerify class action lawsuit alleges, DoubleVerify cut its full-year 2024 revenue outlook due to customers that were pulling back on their ad spending. On this news, the price of DoubleVerify stock fell nearly 39%, according to the complaint. The DoubleVerify class action lawsuit further alleges that on February 27, 2025, DoubleVerify reported lower-than-expected fourth quarter 2024 sales and earnings due in part to reduced customer spending, and defendants further disclosed that the shift of ad dollars from open exchanges to closed platforms was negatively impacting DoubleVerify. On this news, the price of DoubleVerify stock fell more than 36%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired DoubleVerify common stock during the Class Period to seek appointment as lead plaintiff in the DoubleVerify class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the DoubleVerify class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the DoubleVerify class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the DoubleVerify class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@
Malaysian Reserve
21 hours ago
- Malaysian Reserve
URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 6, 2025 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the 'Class Period'), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit. Captioned Cockrell v. UroGen Pharma Ltd., 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen as well as certain of UroGen's top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the UroGen class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: UroGen engages in the development and commercialization of solutions for specialty cancers. According to the complaint, UroGen's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. The UroGen class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) UroGen's ENVISION clinical study for UGN-102 was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (ii) as a result, UroGen would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (iii) UroGen failed to heed the U.S. Food and Drug Administration's ('FDA') warnings about the study design used to support a new drug application ('NDA') for UGN-102; and (iv) as a result, there was a substantial risk that the NDA for UGN-102 would not be approved. The UroGen class action lawsuit further alleges that on May 16, 2025, the FDA published a briefing document in advance of its Oncologic Drugs Advisory Committee meeting regarding UroGen's NDA for UGN-102, which stated that '[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret,' and that the FDA had 'recommended a randomized trial design to the Applicant several times during their product's development due to concerns with interpreting efficacy results' but UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.' On this news, the price of UroGen stock fell nearly 26%, according to the complaint. Then, on May 21, 2025, the UroGen class action lawsuit further alleges that the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk of the investigation therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock fell nearly 45%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired UroGen securities during the Class Period to seek appointment as lead plaintiff in the UroGen class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the UroGen class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the UroGen class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the UroGen class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@
